nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbinoxamine—CYP2C8—Tazarotene—psoriasis	0.0999	0.125	CbGbCtD
Carbinoxamine—CYP2B6—Cholecalciferol—psoriasis	0.0563	0.0704	CbGbCtD
Carbinoxamine—CYP2D6—Hydroxyurea—psoriasis	0.0449	0.0561	CbGbCtD
Carbinoxamine—CYP2C8—Cholecalciferol—psoriasis	0.0426	0.0533	CbGbCtD
Carbinoxamine—CYP2C8—Mycophenolate mofetil—psoriasis	0.037	0.0462	CbGbCtD
Carbinoxamine—CYP2C19—Cholecalciferol—psoriasis	0.0358	0.0447	CbGbCtD
Carbinoxamine—CYP3A4—Calcitriol—psoriasis	0.0336	0.042	CbGbCtD
Carbinoxamine—CYP2C9—Cholecalciferol—psoriasis	0.0297	0.0372	CbGbCtD
Carbinoxamine—CYP2C8—Hydrocortisone—psoriasis	0.0297	0.0371	CbGbCtD
Carbinoxamine—CYP2C8—Cyclosporine—psoriasis	0.028	0.035	CbGbCtD
Carbinoxamine—CYP2D6—Cholecalciferol—psoriasis	0.0272	0.034	CbGbCtD
Carbinoxamine—CYP3A4—Methoxsalen—psoriasis	0.0261	0.0326	CbGbCtD
Carbinoxamine—CYP2C19—Prednisone—psoriasis	0.0248	0.031	CbGbCtD
Carbinoxamine—CYP2E1—Dexamethasone—psoriasis	0.0247	0.0309	CbGbCtD
Carbinoxamine—CYP2B6—Dexamethasone—psoriasis	0.0244	0.0305	CbGbCtD
Carbinoxamine—CYP2C19—Cyclosporine—psoriasis	0.0235	0.0294	CbGbCtD
Carbinoxamine—CYP2C9—Cyclosporine—psoriasis	0.0195	0.0244	CbGbCtD
Carbinoxamine—CYP2C8—Dexamethasone—psoriasis	0.0184	0.0231	CbGbCtD
Carbinoxamine—CYP2D6—Cyclosporine—psoriasis	0.0179	0.0223	CbGbCtD
Carbinoxamine—CYP3A4—Cholecalciferol—psoriasis	0.0173	0.0216	CbGbCtD
Carbinoxamine—CYP2C19—Dexamethasone—psoriasis	0.0155	0.0194	CbGbCtD
Carbinoxamine—CYP3A4—Triamcinolone—psoriasis	0.015	0.0187	CbGbCtD
Carbinoxamine—CYP3A4—Mycophenolate mofetil—psoriasis	0.015	0.0187	CbGbCtD
Carbinoxamine—CYP2C9—Dexamethasone—psoriasis	0.0129	0.0161	CbGbCtD
Carbinoxamine—CYP3A4—Betamethasone—psoriasis	0.0129	0.0161	CbGbCtD
Carbinoxamine—CYP3A4—Prednisolone—psoriasis	0.0127	0.0159	CbGbCtD
Carbinoxamine—CYP3A4—Hydrocortisone—psoriasis	0.012	0.015	CbGbCtD
Carbinoxamine—CYP3A4—Prednisone—psoriasis	0.012	0.015	CbGbCtD
Carbinoxamine—CYP2D6—Dexamethasone—psoriasis	0.0118	0.0147	CbGbCtD
Carbinoxamine—CYP3A4—Cyclosporine—psoriasis	0.0114	0.0142	CbGbCtD
Carbinoxamine—CYP3A4—Dexamethasone—psoriasis	0.00748	0.00936	CbGbCtD
Carbinoxamine—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00273	0.0605	CbGpPWpGaD
Carbinoxamine—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00268	0.0593	CbGpPWpGaD
Carbinoxamine—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00231	0.0512	CbGpPWpGaD
Carbinoxamine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00207	0.0457	CbGpPWpGaD
Carbinoxamine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.0019	0.042	CbGpPWpGaD
Carbinoxamine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00188	0.0417	CbGpPWpGaD
Carbinoxamine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00177	0.0392	CbGpPWpGaD
Carbinoxamine—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00169	0.0375	CbGpPWpGaD
Carbinoxamine—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.00166	0.0367	CbGpPWpGaD
Carbinoxamine—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.00143	0.0317	CbGpPWpGaD
Carbinoxamine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00128	0.0283	CbGpPWpGaD
Carbinoxamine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00118	0.0261	CbGpPWpGaD
Carbinoxamine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00117	0.0258	CbGpPWpGaD
Carbinoxamine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.00077	0.017	CbGpPWpGaD
Carbinoxamine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000704	0.0156	CbGpPWpGaD
Carbinoxamine—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000695	0.0154	CbGpPWpGaD
Carbinoxamine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000689	0.0153	CbGpPWpGaD
Carbinoxamine—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00068	0.0151	CbGpPWpGaD
Carbinoxamine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000596	0.0132	CbGpPWpGaD
Carbinoxamine—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000588	0.013	CbGpPWpGaD
Carbinoxamine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000571	0.0126	CbGpPWpGaD
Carbinoxamine—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000559	0.0124	CbGpPWpGaD
Carbinoxamine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000532	0.0118	CbGpPWpGaD
Carbinoxamine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000525	0.0116	CbGpPWpGaD
Carbinoxamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000489	0.0108	CbGpPWpGaD
Carbinoxamine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000485	0.0107	CbGpPWpGaD
Carbinoxamine—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000483	0.0107	CbGpPWpGaD
Carbinoxamine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000483	0.0107	CbGpPWpGaD
Carbinoxamine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000479	0.0106	CbGpPWpGaD
Carbinoxamine—Vertigo—Mycophenolic acid—psoriasis	0.000448	0.00288	CcSEcCtD
Carbinoxamine—Asthenia—Acitretin—psoriasis	0.000444	0.00286	CcSEcCtD
Carbinoxamine—Vomiting—Calcitriol—psoriasis	0.000442	0.00285	CcSEcCtD
Carbinoxamine—Palpitations—Mycophenolic acid—psoriasis	0.00044	0.00284	CcSEcCtD
Carbinoxamine—Headache—Calcitriol—psoriasis	0.000435	0.0028	CcSEcCtD
Carbinoxamine—Tinnitus—Cyclosporine—psoriasis	0.000432	0.00278	CcSEcCtD
Carbinoxamine—Convulsion—Mycophenolic acid—psoriasis	0.000432	0.00278	CcSEcCtD
Carbinoxamine—Somnolence—Hydroxyurea—psoriasis	0.000432	0.00278	CcSEcCtD
Carbinoxamine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000431	0.00954	CbGpPWpGaD
Carbinoxamine—Sweating increased—Betamethasone—psoriasis	0.000428	0.00276	CcSEcCtD
Carbinoxamine—Sweating increased—Dexamethasone—psoriasis	0.000428	0.00276	CcSEcCtD
Carbinoxamine—Dyspepsia—Hydroxyurea—psoriasis	0.000427	0.00275	CcSEcCtD
Carbinoxamine—Diarrhoea—Acitretin—psoriasis	0.000423	0.00273	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Triamcinolone—psoriasis	0.000423	0.00273	CcSEcCtD
Carbinoxamine—Irritability—Prednisone—psoriasis	0.000422	0.00272	CcSEcCtD
Carbinoxamine—Decreased appetite—Hydroxyurea—psoriasis	0.000422	0.00272	CcSEcCtD
Carbinoxamine—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000422	0.00272	CcSEcCtD
Carbinoxamine—Photosensitivity—Methotrexate—psoriasis	0.000421	0.00271	CcSEcCtD
Carbinoxamine—Tinnitus—Mycophenolate mofetil—psoriasis	0.000421	0.00271	CcSEcCtD
Carbinoxamine—Fatigue—Hydroxyurea—psoriasis	0.000419	0.0027	CcSEcCtD
Carbinoxamine—Chills—Cyclosporine—psoriasis	0.000415	0.00268	CcSEcCtD
Carbinoxamine—Constipation—Hydroxyurea—psoriasis	0.000415	0.00267	CcSEcCtD
Carbinoxamine—Nausea—Calcitriol—psoriasis	0.000413	0.00266	CcSEcCtD
Carbinoxamine—Confusional state—Mycophenolic acid—psoriasis	0.00041	0.00264	CcSEcCtD
Carbinoxamine—Dizziness—Acitretin—psoriasis	0.000409	0.00263	CcSEcCtD
Carbinoxamine—Dizziness—Fluocinolone Acetonide—psoriasis	0.000408	0.00263	CcSEcCtD
Carbinoxamine—Chills—Mycophenolate mofetil—psoriasis	0.000405	0.00261	CcSEcCtD
Carbinoxamine—Feeling abnormal—Hydroxyurea—psoriasis	0.0004	0.00258	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000398	0.00256	CcSEcCtD
Carbinoxamine—Tachycardia—Mycophenolic acid—psoriasis	0.000397	0.00256	CcSEcCtD
Carbinoxamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000397	0.00877	CbGpPWpGaD
Carbinoxamine—Tension—Cyclosporine—psoriasis	0.000396	0.00255	CcSEcCtD
Carbinoxamine—Vomiting—Acitretin—psoriasis	0.000393	0.00253	CcSEcCtD
Carbinoxamine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000393	0.0087	CbGpPWpGaD
Carbinoxamine—Hyperhidrosis—Mycophenolic acid—psoriasis	0.000393	0.00253	CcSEcCtD
Carbinoxamine—Vomiting—Fluocinolone Acetonide—psoriasis	0.000392	0.00253	CcSEcCtD
Carbinoxamine—Nervousness—Cyclosporine—psoriasis	0.000391	0.00252	CcSEcCtD
Carbinoxamine—Anorexia—Mycophenolic acid—psoriasis	0.000388	0.0025	CcSEcCtD
Carbinoxamine—Headache—Acitretin—psoriasis	0.000387	0.0025	CcSEcCtD
Carbinoxamine—Headache—Fluocinolone Acetonide—psoriasis	0.000386	0.00249	CcSEcCtD
Carbinoxamine—Tension—Mycophenolate mofetil—psoriasis	0.000386	0.00249	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Betamethasone—psoriasis	0.000384	0.00247	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Dexamethasone—psoriasis	0.000384	0.00247	CcSEcCtD
Carbinoxamine—Nervousness—Mycophenolate mofetil—psoriasis	0.000382	0.00246	CcSEcCtD
Carbinoxamine—Hypotension—Mycophenolic acid—psoriasis	0.00038	0.00245	CcSEcCtD
Carbinoxamine—Vision blurred—Cyclosporine—psoriasis	0.00038	0.00245	CcSEcCtD
Carbinoxamine—Tremor—Cyclosporine—psoriasis	0.000378	0.00243	CcSEcCtD
Carbinoxamine—Sweating increased—Prednisone—psoriasis	0.000373	0.0024	CcSEcCtD
Carbinoxamine—Agitation—Cyclosporine—psoriasis	0.00037	0.00239	CcSEcCtD
Carbinoxamine—Tremor—Mycophenolate mofetil—psoriasis	0.000368	0.00237	CcSEcCtD
Carbinoxamine—Insomnia—Mycophenolic acid—psoriasis	0.000368	0.00237	CcSEcCtD
Carbinoxamine—Nausea—Acitretin—psoriasis	0.000367	0.00237	CcSEcCtD
Carbinoxamine—Nausea—Fluocinolone Acetonide—psoriasis	0.000366	0.00236	CcSEcCtD
Carbinoxamine—Paraesthesia—Mycophenolic acid—psoriasis	0.000365	0.00235	CcSEcCtD
Carbinoxamine—Vertigo—Cyclosporine—psoriasis	0.000362	0.00233	CcSEcCtD
Carbinoxamine—Somnolence—Mycophenolic acid—psoriasis	0.000361	0.00233	CcSEcCtD
Carbinoxamine—Agitation—Mycophenolate mofetil—psoriasis	0.000361	0.00233	CcSEcCtD
Carbinoxamine—Dyspepsia—Mycophenolic acid—psoriasis	0.000358	0.00231	CcSEcCtD
Carbinoxamine—Decreased appetite—Mycophenolic acid—psoriasis	0.000353	0.00228	CcSEcCtD
Carbinoxamine—Vertigo—Mycophenolate mofetil—psoriasis	0.000353	0.00228	CcSEcCtD
Carbinoxamine—Irritability—Methotrexate—psoriasis	0.000353	0.00227	CcSEcCtD
Carbinoxamine—Fatigue—Mycophenolic acid—psoriasis	0.000351	0.00226	CcSEcCtD
Carbinoxamine—Convulsion—Cyclosporine—psoriasis	0.000349	0.00225	CcSEcCtD
Carbinoxamine—Asthenia—Hydroxyurea—psoriasis	0.000348	0.00224	CcSEcCtD
Carbinoxamine—Constipation—Mycophenolic acid—psoriasis	0.000348	0.00224	CcSEcCtD
Carbinoxamine—Palpitations—Mycophenolate mofetil—psoriasis	0.000347	0.00224	CcSEcCtD
Carbinoxamine—Vision blurred—Prednisolone—psoriasis	0.000346	0.00223	CcSEcCtD
Carbinoxamine—Convulsion—Mycophenolate mofetil—psoriasis	0.000341	0.00219	CcSEcCtD
Carbinoxamine—Feeling abnormal—Mycophenolic acid—psoriasis	0.000335	0.00216	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Prednisone—psoriasis	0.000334	0.00215	CcSEcCtD
Carbinoxamine—Diarrhoea—Hydroxyurea—psoriasis	0.000332	0.00214	CcSEcCtD
Carbinoxamine—Confusional state—Cyclosporine—psoriasis	0.000332	0.00214	CcSEcCtD
Carbinoxamine—Vertigo—Prednisolone—psoriasis	0.00033	0.00212	CcSEcCtD
Carbinoxamine—Confusional state—Mycophenolate mofetil—psoriasis	0.000324	0.00208	CcSEcCtD
Carbinoxamine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000323	0.00715	CbGpPWpGaD
Carbinoxamine—Thrombocytopenia—Cyclosporine—psoriasis	0.000322	0.00207	CcSEcCtD
Carbinoxamine—Vertigo—Hydrocortisone—psoriasis	0.000322	0.00207	CcSEcCtD
Carbinoxamine—Dizziness—Hydroxyurea—psoriasis	0.000321	0.00207	CcSEcCtD
Carbinoxamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00032	0.00708	CbGpPWpGaD
Carbinoxamine—Hyperhidrosis—Cyclosporine—psoriasis	0.000318	0.00205	CcSEcCtD
Carbinoxamine—Convulsion—Prednisolone—psoriasis	0.000318	0.00205	CcSEcCtD
Carbinoxamine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000317	0.00701	CbGpPWpGaD
Carbinoxamine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000316	0.00698	CbGpPWpGaD
Carbinoxamine—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000314	0.00202	CcSEcCtD
Carbinoxamine—Anorexia—Cyclosporine—psoriasis	0.000314	0.00202	CcSEcCtD
Carbinoxamine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000313	0.00202	CcSEcCtD
Carbinoxamine—Convulsion—Hydrocortisone—psoriasis	0.00031	0.002	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.00031	0.002	CcSEcCtD
Carbinoxamine—Vomiting—Hydroxyurea—psoriasis	0.000309	0.00199	CcSEcCtD
Carbinoxamine—Anorexia—Mycophenolate mofetil—psoriasis	0.000306	0.00197	CcSEcCtD
Carbinoxamine—Headache—Hydroxyurea—psoriasis	0.000304	0.00196	CcSEcCtD
Carbinoxamine—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000303	0.00671	CbGpPWpGaD
Carbinoxamine—Vertigo—Triamcinolone—psoriasis	0.000303	0.00195	CcSEcCtD
Carbinoxamine—Hypotension—Mycophenolate mofetil—psoriasis	0.0003	0.00193	CcSEcCtD
Carbinoxamine—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000299	0.00661	CbGpPWpGaD
Carbinoxamine—Insomnia—Cyclosporine—psoriasis	0.000298	0.00192	CcSEcCtD
Carbinoxamine—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000297	0.00657	CbGpPWpGaD
Carbinoxamine—Paraesthesia—Cyclosporine—psoriasis	0.000295	0.0019	CcSEcCtD
Carbinoxamine—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000293	0.00648	CbGpPWpGaD
Carbinoxamine—Somnolence—Cyclosporine—psoriasis	0.000292	0.00188	CcSEcCtD
Carbinoxamine—Convulsion—Triamcinolone—psoriasis	0.000292	0.00188	CcSEcCtD
Carbinoxamine—Tachycardia—Prednisolone—psoriasis	0.000292	0.00188	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Methotrexate—psoriasis	0.000292	0.00188	CcSEcCtD
Carbinoxamine—Asthenia—Mycophenolic acid—psoriasis	0.000292	0.00188	CcSEcCtD
Carbinoxamine—Insomnia—Mycophenolate mofetil—psoriasis	0.00029	0.00187	CcSEcCtD
Carbinoxamine—Dyspepsia—Cyclosporine—psoriasis	0.00029	0.00187	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Prednisolone—psoriasis	0.000289	0.00186	CcSEcCtD
Carbinoxamine—Nausea—Hydroxyurea—psoriasis	0.000288	0.00186	CcSEcCtD
Carbinoxamine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000288	0.00186	CcSEcCtD
Carbinoxamine—Decreased appetite—Cyclosporine—psoriasis	0.000286	0.00184	CcSEcCtD
Carbinoxamine—Tachycardia—Hydrocortisone—psoriasis	0.000285	0.00184	CcSEcCtD
Carbinoxamine—Somnolence—Mycophenolate mofetil—psoriasis	0.000285	0.00184	CcSEcCtD
Carbinoxamine—Drowsiness—Methotrexate—psoriasis	0.000285	0.00184	CcSEcCtD
Carbinoxamine—Fatigue—Cyclosporine—psoriasis	0.000284	0.00183	CcSEcCtD
Carbinoxamine—HRH1—IL-4 Signaling Pathway—SOCS1—psoriasis	0.000283	0.00627	CbGpPWpGaD
Carbinoxamine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000283	0.00182	CcSEcCtD
Carbinoxamine—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000282	0.00182	CcSEcCtD
Carbinoxamine—Constipation—Cyclosporine—psoriasis	0.000281	0.00181	CcSEcCtD
Carbinoxamine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000279	0.0018	CcSEcCtD
Carbinoxamine—Anorexia—Hydrocortisone—psoriasis	0.000279	0.0018	CcSEcCtD
Carbinoxamine—Diarrhoea—Mycophenolic acid—psoriasis	0.000278	0.00179	CcSEcCtD
Carbinoxamine—Vertigo—Dexamethasone—psoriasis	0.000275	0.00177	CcSEcCtD
Carbinoxamine—Vertigo—Betamethasone—psoriasis	0.000275	0.00177	CcSEcCtD
Carbinoxamine—Constipation—Mycophenolate mofetil—psoriasis	0.000274	0.00177	CcSEcCtD
Carbinoxamine—Hypotension—Hydrocortisone—psoriasis	0.000273	0.00176	CcSEcCtD
Carbinoxamine—Feeling abnormal—Cyclosporine—psoriasis	0.000271	0.00175	CcSEcCtD
Carbinoxamine—Insomnia—Prednisolone—psoriasis	0.000271	0.00174	CcSEcCtD
Carbinoxamine—Dizziness—Mycophenolic acid—psoriasis	0.000269	0.00173	CcSEcCtD
Carbinoxamine—Paraesthesia—Prednisolone—psoriasis	0.000269	0.00173	CcSEcCtD
Carbinoxamine—Tachycardia—Triamcinolone—psoriasis	0.000269	0.00173	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Triamcinolone—psoriasis	0.000266	0.00171	CcSEcCtD
Carbinoxamine—Agranulocytosis—Methotrexate—psoriasis	0.000266	0.00171	CcSEcCtD
Carbinoxamine—Convulsion—Dexamethasone—psoriasis	0.000265	0.00171	CcSEcCtD
Carbinoxamine—Convulsion—Betamethasone—psoriasis	0.000265	0.00171	CcSEcCtD
Carbinoxamine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000264	0.0017	CcSEcCtD
Carbinoxamine—Insomnia—Hydrocortisone—psoriasis	0.000264	0.0017	CcSEcCtD
Carbinoxamine—Paraesthesia—Hydrocortisone—psoriasis	0.000263	0.00169	CcSEcCtD
Carbinoxamine—Urticaria—Cyclosporine—psoriasis	0.000261	0.00168	CcSEcCtD
Carbinoxamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000259	0.00574	CbGpPWpGaD
Carbinoxamine—Vomiting—Mycophenolic acid—psoriasis	0.000259	0.00167	CcSEcCtD
Carbinoxamine—Dyspepsia—Hydrocortisone—psoriasis	0.000257	0.00166	CcSEcCtD
Carbinoxamine—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000257	0.00568	CbGpPWpGaD
Carbinoxamine—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000256	0.00567	CbGpPWpGaD
Carbinoxamine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000256	0.00566	CbGpPWpGaD
Carbinoxamine—Urticaria—Mycophenolate mofetil—psoriasis	0.000255	0.00164	CcSEcCtD
Carbinoxamine—Headache—Mycophenolic acid—psoriasis	0.000255	0.00164	CcSEcCtD
Carbinoxamine—Decreased appetite—Hydrocortisone—psoriasis	0.000254	0.00164	CcSEcCtD
Carbinoxamine—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000253	0.0056	CbGpPWpGaD
Carbinoxamine—Fatigue—Hydrocortisone—psoriasis	0.000252	0.00162	CcSEcCtD
Carbinoxamine—Vision blurred—Prednisone—psoriasis	0.000251	0.00162	CcSEcCtD
Carbinoxamine—Insomnia—Triamcinolone—psoriasis	0.000249	0.0016	CcSEcCtD
Carbinoxamine—Paraesthesia—Triamcinolone—psoriasis	0.000247	0.00159	CcSEcCtD
Carbinoxamine—HRH1—IL-4 Signaling Pathway—IL4—psoriasis	0.000247	0.00547	CbGpPWpGaD
Carbinoxamine—Feeling abnormal—Prednisolone—psoriasis	0.000247	0.00159	CcSEcCtD
Carbinoxamine—Agitation—Prednisone—psoriasis	0.000245	0.00158	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Betamethasone—psoriasis	0.000245	0.00158	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Dexamethasone—psoriasis	0.000245	0.00158	CcSEcCtD
Carbinoxamine—Tachycardia—Dexamethasone—psoriasis	0.000244	0.00157	CcSEcCtD
Carbinoxamine—Tachycardia—Betamethasone—psoriasis	0.000244	0.00157	CcSEcCtD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000243	0.00537	CbGpPWpGaD
Carbinoxamine—Dyspepsia—Triamcinolone—psoriasis	0.000242	0.00156	CcSEcCtD
Carbinoxamine—Nausea—Mycophenolic acid—psoriasis	0.000242	0.00156	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Dexamethasone—psoriasis	0.000241	0.00156	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Betamethasone—psoriasis	0.000241	0.00156	CcSEcCtD
Carbinoxamine—Feeling abnormal—Hydrocortisone—psoriasis	0.000241	0.00155	CcSEcCtD
Carbinoxamine—Vertigo—Prednisone—psoriasis	0.000239	0.00154	CcSEcCtD
Carbinoxamine—Tinnitus—Methotrexate—psoriasis	0.000239	0.00154	CcSEcCtD
Carbinoxamine—Anorexia—Betamethasone—psoriasis	0.000238	0.00153	CcSEcCtD
Carbinoxamine—Anorexia—Dexamethasone—psoriasis	0.000238	0.00153	CcSEcCtD
Carbinoxamine—Urticaria—Prednisolone—psoriasis	0.000238	0.00153	CcSEcCtD
Carbinoxamine—Fatigue—Triamcinolone—psoriasis	0.000237	0.00153	CcSEcCtD
Carbinoxamine—Asthenia—Cyclosporine—psoriasis	0.000236	0.00152	CcSEcCtD
Carbinoxamine—Hypotension—Dexamethasone—psoriasis	0.000233	0.0015	CcSEcCtD
Carbinoxamine—Hypotension—Betamethasone—psoriasis	0.000233	0.0015	CcSEcCtD
Carbinoxamine—Urticaria—Hydrocortisone—psoriasis	0.000232	0.0015	CcSEcCtD
Carbinoxamine—Convulsion—Prednisone—psoriasis	0.000231	0.00149	CcSEcCtD
Carbinoxamine—Asthenia—Mycophenolate mofetil—psoriasis	0.00023	0.00148	CcSEcCtD
Carbinoxamine—Chills—Methotrexate—psoriasis	0.00023	0.00148	CcSEcCtD
Carbinoxamine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000229	0.00507	CbGpPWpGaD
Carbinoxamine—Feeling abnormal—Triamcinolone—psoriasis	0.000227	0.00146	CcSEcCtD
Carbinoxamine—Insomnia—Dexamethasone—psoriasis	0.000226	0.00146	CcSEcCtD
Carbinoxamine—Insomnia—Betamethasone—psoriasis	0.000226	0.00146	CcSEcCtD
Carbinoxamine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000226	0.005	CbGpPWpGaD
Carbinoxamine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000225	0.00499	CbGpPWpGaD
Carbinoxamine—Diarrhoea—Cyclosporine—psoriasis	0.000225	0.00145	CcSEcCtD
Carbinoxamine—Paraesthesia—Dexamethasone—psoriasis	0.000224	0.00144	CcSEcCtD
Carbinoxamine—Paraesthesia—Betamethasone—psoriasis	0.000224	0.00144	CcSEcCtD
Carbinoxamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000223	0.00493	CbGpPWpGaD
Carbinoxamine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000222	0.00491	CbGpPWpGaD
Carbinoxamine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000221	0.00488	CbGpPWpGaD
Carbinoxamine—Dyspepsia—Betamethasone—psoriasis	0.00022	0.00142	CcSEcCtD
Carbinoxamine—Dyspepsia—Dexamethasone—psoriasis	0.00022	0.00142	CcSEcCtD
Carbinoxamine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00022	0.00141	CcSEcCtD
Carbinoxamine—Urticaria—Triamcinolone—psoriasis	0.000219	0.00141	CcSEcCtD
Carbinoxamine—Dizziness—Cyclosporine—psoriasis	0.000218	0.0014	CcSEcCtD
Carbinoxamine—Decreased appetite—Dexamethasone—psoriasis	0.000217	0.0014	CcSEcCtD
Carbinoxamine—Decreased appetite—Betamethasone—psoriasis	0.000217	0.0014	CcSEcCtD
Carbinoxamine—Fatigue—Dexamethasone—psoriasis	0.000215	0.00139	CcSEcCtD
Carbinoxamine—Fatigue—Betamethasone—psoriasis	0.000215	0.00139	CcSEcCtD
Carbinoxamine—Tachycardia—Prednisone—psoriasis	0.000212	0.00137	CcSEcCtD
Carbinoxamine—Dizziness—Mycophenolate mofetil—psoriasis	0.000212	0.00137	CcSEcCtD
Carbinoxamine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000211	0.00466	CbGpPWpGaD
Carbinoxamine—Hyperhidrosis—Prednisone—psoriasis	0.00021	0.00135	CcSEcCtD
Carbinoxamine—Vision blurred—Methotrexate—psoriasis	0.00021	0.00135	CcSEcCtD
Carbinoxamine—Asthenia—Hydrocortisone—psoriasis	0.00021	0.00135	CcSEcCtD
Carbinoxamine—Vomiting—Cyclosporine—psoriasis	0.000209	0.00135	CcSEcCtD
Carbinoxamine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000209	0.00462	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000208	0.0046	CbGpPWpGaD
Carbinoxamine—Anorexia—Prednisone—psoriasis	0.000207	0.00134	CcSEcCtD
Carbinoxamine—Headache—Cyclosporine—psoriasis	0.000206	0.00133	CcSEcCtD
Carbinoxamine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000206	0.00456	CbGpPWpGaD
Carbinoxamine—Feeling abnormal—Betamethasone—psoriasis	0.000206	0.00133	CcSEcCtD
Carbinoxamine—Feeling abnormal—Dexamethasone—psoriasis	0.000206	0.00133	CcSEcCtD
Carbinoxamine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000204	0.00452	CbGpPWpGaD
Carbinoxamine—Vomiting—Mycophenolate mofetil—psoriasis	0.000204	0.00131	CcSEcCtD
Carbinoxamine—Headache—Mycophenolate mofetil—psoriasis	0.000201	0.00129	CcSEcCtD
Carbinoxamine—Vertigo—Methotrexate—psoriasis	0.0002	0.00129	CcSEcCtD
Carbinoxamine—Diarrhoea—Hydrocortisone—psoriasis	0.0002	0.00129	CcSEcCtD
Carbinoxamine—Urticaria—Betamethasone—psoriasis	0.000198	0.00128	CcSEcCtD
Carbinoxamine—Urticaria—Dexamethasone—psoriasis	0.000198	0.00128	CcSEcCtD
Carbinoxamine—Dizziness—Prednisolone—psoriasis	0.000198	0.00128	CcSEcCtD
Carbinoxamine—Asthenia—Triamcinolone—psoriasis	0.000198	0.00127	CcSEcCtD
Carbinoxamine—Insomnia—Prednisone—psoriasis	0.000197	0.00127	CcSEcCtD
Carbinoxamine—Nausea—Cyclosporine—psoriasis	0.000195	0.00126	CcSEcCtD
Carbinoxamine—Paraesthesia—Prednisone—psoriasis	0.000195	0.00126	CcSEcCtD
Carbinoxamine—HRH1—IL-4 Signaling Pathway—NFKBIA—psoriasis	0.000195	0.00431	CbGpPWpGaD
Carbinoxamine—Dizziness—Hydrocortisone—psoriasis	0.000193	0.00125	CcSEcCtD
Carbinoxamine—Convulsion—Methotrexate—psoriasis	0.000193	0.00124	CcSEcCtD
Carbinoxamine—Dyspepsia—Prednisone—psoriasis	0.000191	0.00123	CcSEcCtD
Carbinoxamine—Nausea—Mycophenolate mofetil—psoriasis	0.000191	0.00123	CcSEcCtD
Carbinoxamine—Decreased appetite—Prednisone—psoriasis	0.000189	0.00122	CcSEcCtD
Carbinoxamine—Fatigue—Prednisone—psoriasis	0.000188	0.00121	CcSEcCtD
Carbinoxamine—Headache—Prednisolone—psoriasis	0.000188	0.00121	CcSEcCtD
Carbinoxamine—Constipation—Prednisone—psoriasis	0.000186	0.0012	CcSEcCtD
Carbinoxamine—Vomiting—Hydrocortisone—psoriasis	0.000186	0.0012	CcSEcCtD
Carbinoxamine—HRH1—GPCR ligand binding—HCAR2—psoriasis	0.000185	0.00409	CbGpPWpGaD
Carbinoxamine—Confusional state—Methotrexate—psoriasis	0.000183	0.00118	CcSEcCtD
Carbinoxamine—Headache—Hydrocortisone—psoriasis	0.000183	0.00118	CcSEcCtD
Carbinoxamine—Dizziness—Triamcinolone—psoriasis	0.000182	0.00117	CcSEcCtD
Carbinoxamine—Feeling abnormal—Prednisone—psoriasis	0.000179	0.00115	CcSEcCtD
Carbinoxamine—Asthenia—Betamethasone—psoriasis	0.000179	0.00115	CcSEcCtD
Carbinoxamine—Asthenia—Dexamethasone—psoriasis	0.000179	0.00115	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Methotrexate—psoriasis	0.000178	0.00115	CcSEcCtD
Carbinoxamine—Nausea—Prednisolone—psoriasis	0.000178	0.00115	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Methotrexate—psoriasis	0.000176	0.00113	CcSEcCtD
Carbinoxamine—Vomiting—Triamcinolone—psoriasis	0.000175	0.00113	CcSEcCtD
Carbinoxamine—Nausea—Hydrocortisone—psoriasis	0.000174	0.00112	CcSEcCtD
Carbinoxamine—Anorexia—Methotrexate—psoriasis	0.000173	0.00112	CcSEcCtD
Carbinoxamine—Urticaria—Prednisone—psoriasis	0.000173	0.00111	CcSEcCtD
Carbinoxamine—Headache—Triamcinolone—psoriasis	0.000172	0.00111	CcSEcCtD
Carbinoxamine—Diarrhoea—Dexamethasone—psoriasis	0.000171	0.0011	CcSEcCtD
Carbinoxamine—Diarrhoea—Betamethasone—psoriasis	0.000171	0.0011	CcSEcCtD
Carbinoxamine—Hypotension—Methotrexate—psoriasis	0.00017	0.00109	CcSEcCtD
Carbinoxamine—Dizziness—Betamethasone—psoriasis	0.000165	0.00106	CcSEcCtD
Carbinoxamine—Dizziness—Dexamethasone—psoriasis	0.000165	0.00106	CcSEcCtD
Carbinoxamine—Insomnia—Methotrexate—psoriasis	0.000164	0.00106	CcSEcCtD
Carbinoxamine—Nausea—Triamcinolone—psoriasis	0.000164	0.00105	CcSEcCtD
Carbinoxamine—Paraesthesia—Methotrexate—psoriasis	0.000163	0.00105	CcSEcCtD
Carbinoxamine—Somnolence—Methotrexate—psoriasis	0.000162	0.00104	CcSEcCtD
Carbinoxamine—Dyspepsia—Methotrexate—psoriasis	0.00016	0.00103	CcSEcCtD
Carbinoxamine—HRH1—IL-4 Signaling Pathway—TYK2—psoriasis	0.00016	0.00353	CbGpPWpGaD
Carbinoxamine—Vomiting—Betamethasone—psoriasis	0.000159	0.00102	CcSEcCtD
Carbinoxamine—Vomiting—Dexamethasone—psoriasis	0.000159	0.00102	CcSEcCtD
Carbinoxamine—Decreased appetite—Methotrexate—psoriasis	0.000158	0.00102	CcSEcCtD
Carbinoxamine—Fatigue—Methotrexate—psoriasis	0.000157	0.00101	CcSEcCtD
Carbinoxamine—Headache—Dexamethasone—psoriasis	0.000156	0.00101	CcSEcCtD
Carbinoxamine—Headache—Betamethasone—psoriasis	0.000156	0.00101	CcSEcCtD
Carbinoxamine—Asthenia—Prednisone—psoriasis	0.000156	0.00101	CcSEcCtD
Carbinoxamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000155	0.00344	CbGpPWpGaD
Carbinoxamine—Feeling abnormal—Methotrexate—psoriasis	0.00015	0.000965	CcSEcCtD
Carbinoxamine—Diarrhoea—Prednisone—psoriasis	0.000149	0.000959	CcSEcCtD
Carbinoxamine—Nausea—Dexamethasone—psoriasis	0.000148	0.000956	CcSEcCtD
Carbinoxamine—Nausea—Betamethasone—psoriasis	0.000148	0.000956	CcSEcCtD
Carbinoxamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000147	0.00325	CbGpPWpGaD
Carbinoxamine—Urticaria—Methotrexate—psoriasis	0.000144	0.00093	CcSEcCtD
Carbinoxamine—Dizziness—Prednisone—psoriasis	0.000144	0.000927	CcSEcCtD
Carbinoxamine—Vomiting—Prednisone—psoriasis	0.000138	0.000891	CcSEcCtD
Carbinoxamine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000138	0.00305	CbGpPWpGaD
Carbinoxamine—Headache—Prednisone—psoriasis	0.000136	0.000878	CcSEcCtD
Carbinoxamine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000136	0.00301	CbGpPWpGaD
Carbinoxamine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000132	0.00292	CbGpPWpGaD
Carbinoxamine—Asthenia—Methotrexate—psoriasis	0.00013	0.00084	CcSEcCtD
Carbinoxamine—Nausea—Prednisone—psoriasis	0.000129	0.000832	CcSEcCtD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000126	0.00279	CbGpPWpGaD
Carbinoxamine—Diarrhoea—Methotrexate—psoriasis	0.000124	0.000801	CcSEcCtD
Carbinoxamine—HRH1—IL-4 Signaling Pathway—NFKB1—psoriasis	0.000124	0.00275	CbGpPWpGaD
Carbinoxamine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000121	0.00269	CbGpPWpGaD
Carbinoxamine—Dizziness—Methotrexate—psoriasis	0.00012	0.000774	CcSEcCtD
Carbinoxamine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000119	0.00263	CbGpPWpGaD
Carbinoxamine—Vomiting—Methotrexate—psoriasis	0.000116	0.000745	CcSEcCtD
Carbinoxamine—Headache—Methotrexate—psoriasis	0.000114	0.000734	CcSEcCtD
Carbinoxamine—HRH1—IL-4 Signaling Pathway—STAT3—psoriasis	0.000112	0.00247	CbGpPWpGaD
Carbinoxamine—Nausea—Methotrexate—psoriasis	0.000108	0.000696	CcSEcCtD
Carbinoxamine—HRH1—GPCR downstream signaling—HCAR2—psoriasis	0.000105	0.00231	CbGpPWpGaD
Carbinoxamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000102	0.00227	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CCL20—psoriasis	9.61e-05	0.00213	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—HCAR2—psoriasis	9.49e-05	0.0021	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—NDUFA5—psoriasis	6.1e-05	0.00135	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—NDUFA5—psoriasis	5.97e-05	0.00132	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—HCAR2—psoriasis	5.61e-05	0.00124	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CCL20—psoriasis	5.43e-05	0.0012	CbGpPWpGaD
Carbinoxamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	5.28e-05	0.00117	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CYP2S1—psoriasis	5.18e-05	0.00115	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—NDUFA5—psoriasis	5.16e-05	0.00114	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CYP2S1—psoriasis	5.08e-05	0.00112	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CCL20—psoriasis	4.93e-05	0.00109	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TAGAP—psoriasis	4.86e-05	0.00108	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.81e-05	0.00106	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—NDUFA5—psoriasis	4.61e-05	0.00102	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CYP2S1—psoriasis	4.39e-05	0.000971	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.29e-05	0.00095	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—NDUFA5—psoriasis	4.24e-05	0.000937	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—NDUFA5—psoriasis	4.2e-05	0.000929	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CYP2S1—psoriasis	3.92e-05	0.000867	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.92e-05	0.000866	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CYP2S1—psoriasis	3.6e-05	0.000797	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP2S1—psoriasis	3.57e-05	0.00079	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.41e-05	0.000754	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CCL20—psoriasis	2.91e-05	0.000644	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NDUFA5—psoriasis	2.77e-05	0.000613	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CXCL8—psoriasis	2.59e-05	0.000574	CbGpPWpGaD
Carbinoxamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.58e-05	0.000572	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CARM1—psoriasis	2.53e-05	0.00056	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CARM1—psoriasis	2.48e-05	0.000549	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP2S1—psoriasis	2.36e-05	0.000521	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.3e-05	0.000509	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CARM1—psoriasis	2.14e-05	0.000474	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.05e-05	0.000454	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2e-05	0.000443	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CARM1—psoriasis	1.91e-05	0.000423	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.87e-05	0.000414	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.79e-05	0.000396	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CARM1—psoriasis	1.76e-05	0.000389	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CARM1—psoriasis	1.74e-05	0.000386	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.63e-05	0.000361	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—SOCS1—psoriasis	1.6e-05	0.000355	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CAT—psoriasis	1.56e-05	0.000344	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—TYK2—psoriasis	1.53e-05	0.000338	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CAT—psoriasis	1.52e-05	0.000337	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CXCL8—psoriasis	1.47e-05	0.000324	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CXCL8—psoriasis	1.33e-05	0.000295	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CAT—psoriasis	1.32e-05	0.000292	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—APOE—psoriasis	1.21e-05	0.000268	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—APOE—psoriasis	1.18e-05	0.000262	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—LEP—psoriasis	1.18e-05	0.000262	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—APOE—psoriasis	1.18e-05	0.000262	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CAT—psoriasis	1.18e-05	0.00026	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CARM1—psoriasis	1.15e-05	0.000254	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—NFKBIA—psoriasis	1.1e-05	0.000244	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CAT—psoriasis	1.08e-05	0.000239	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CAT—psoriasis	1.07e-05	0.000237	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PPARG—psoriasis	1.05e-05	0.000233	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PPARG—psoriasis	1.03e-05	0.000228	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—APOE—psoriasis	1.02e-05	0.000227	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—APOE—psoriasis	9.14e-06	0.000202	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TYK2—psoriasis	9.03e-06	0.0002	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PPARG—psoriasis	8.92e-06	0.000197	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—APOE—psoriasis	8.41e-06	0.000186	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—APOE—psoriasis	8.33e-06	0.000184	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PPARG—psoriasis	7.96e-06	0.000176	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CXCL8—psoriasis	7.86e-06	0.000174	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—IL6—psoriasis	7.48e-06	0.000165	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PPARG—psoriasis	7.32e-06	0.000162	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—JUN—psoriasis	7.31e-06	0.000162	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PPARG—psoriasis	7.26e-06	0.000161	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CAT—psoriasis	7.07e-06	0.000157	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—NFKB1—psoriasis	7.04e-06	0.000156	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—VEGFA—psoriasis	6.39e-06	0.000141	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—STAT3—psoriasis	6.32e-06	0.00014	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—APOE—psoriasis	5.5e-06	0.000122	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TP53—psoriasis	4.83e-06	0.000107	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PPARG—psoriasis	4.79e-06	0.000106	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IL6—psoriasis	4.42e-06	9.77e-05	CbGpPWpGaD
